Advertisement
New Zealand markets closed
  • NZX 50

    11,805.09
    -141.34 (-1.18%)
     
  • NZD/USD

    0.5946
    -0.0004 (-0.06%)
     
  • NZD/EUR

    0.5550
    +0.0010 (+0.18%)
     
  • ALL ORDS

    7,837.40
    -100.10 (-1.26%)
     
  • ASX 200

    7,575.90
    -107.10 (-1.39%)
     
  • OIL

    83.78
    +0.21 (+0.25%)
     
  • GOLD

    2,350.40
    +7.90 (+0.34%)
     
  • NASDAQ

    17,755.37
    +324.87 (+1.86%)
     
  • FTSE

    8,139.83
    +60.97 (+0.75%)
     
  • Dow Jones

    38,290.63
    +204.83 (+0.54%)
     
  • DAX

    18,161.01
    +243.73 (+1.36%)
     
  • Hang Seng

    17,651.15
    +366.61 (+2.12%)
     
  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     
  • NZD/JPY

    93.7740
    +1.2780 (+1.38%)
     

1 Hot Growth Stock to Buy, and 1 to Avoid (For Now)

On that note, Pfizer (NYSE: PFE) and BioNTech (NASDAQ: BNTX) worked together to develop and commercialize their coronavirus vaccine, Comirnaty. In BioNTech's second quarter, practically 100% of its product sales, totaling around $3.3 billion, were attributable to its share of jab revenue.